Peroxisome proliferator-activated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis

Current Opinion in Lipidology

Volumn 10, Issue 3, 1999, Pages 245-257

  Fruchart, Jean Charles ^a,b   Duriez, Patrick ^a   Staels, Bart ^a  

^a INSERM   (France)

^b INSTITUT PASTEUR DE LILLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; APOLIPOPROTEIN C3; CARNITINE PALMITOYLTRANSFERASE; CIPROFIBRATE; CLOFIBRATE; CYCLOOXYGENASE 2; ENDOTHELIN 1; ESTRADIOL; FATTY ACID; FENOFIBRATE; FENOFIBRIC ACID; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 6; LIPOPROTEIN LIPASE; LONG CHAIN FATTY ACID COENZYME A LIGASE; NITRIC OXIDE SYNTHASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PIRINIXIC ACID; THROMBIN; TRANSCRIPTION FACTOR AP 1; TRIACYLGLYCEROL; TROGLITAZONE; UNINDEXED DRUG;

APOPTOSIS; ATHEROGENESIS; ATHEROSCLEROSIS; BLOOD VESSEL WALL; CARDIOVASCULAR INFLAMMATION; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DOSE RESPONSE; DRUG MECHANISM; DRUG RECEPTOR BINDING; DYSLIPIDEMIA; ENDOTHELIUM; ENZYME ACTIVITY; ESTERIFICATION; FATTY ACID TRANSPORT; GENE CONTROL; HEART MUSCLE; HEPATOMEGALY; HUMAN; LIPID OXIDATION; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; LIVER METABOLISM; MACROPHAGE; MONOCYTE; NONHUMAN; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SKELETAL MUSCLE; SMOOTH MUSCLE FIBER; THROMBOSIS; TRANSCRIPTION REGULATION;

ANIMALS; ANTILIPEMIC AGENTS; ARTERIOSCLEROSIS; GENE EXPRESSION REGULATION; HUMANS; LIPOPROTEINS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TRANSCRIPTION FACTORS; VASCULITIS;

EID: 0032816777     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041433-199906000-00007     Document Type: Review

References (99)

1. 1 Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333:1301-1307.
2. 2 Scandinavian Sinvartatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344:1383-1389.
3. 3 Sacks FM, Moye LA, Davis BR, Coles TG, Rouleau JL, Nash DT, et al. Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial. Circulation 1998; 97:1446-1452.
4. 4 Sprecher DL. Triglycerides as a risk factor for coronary artery disease. Am J Cardiol 1998; 82:49U-56U.
5. 5 Saku K, Zhang B, Ohta T, Arakawa K. Quantity and function of high density lipoprotein as an indicator of coronary atherosclerosis. J Am Coll Cardiol 1999; 33:436-443.
6. 6 Askanas Z, Malanowicz W, Zambrowicz K. Effect of Atromid on plasma lipids and fibrinolysis in patients with a history of myocardial infarct. Pol Arch Med Wewn 1965; 35:5-11.
7. 7 Orsetti A, Mirouze J. Effect of ethyl alpha-p-chlorophenoxyisobutyrate (Clofibrate) on lipids, cholesterol and uric acid in diabetes mellitus. Therapie 1966; 21:685-691.
8. 8 Prevention of coronary heart disease: scientific background and new clinical guidelines: recommendations of the European Atherosclerosis Society prepared by International Task Force for Prevention of Coronary Heart Disease. Nutr Metab Cardiovasc Dis 1992; 2:113-156.
9. 9 Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA 1993; 269:3015-3023.
10. 10 Rubins HB. Veterans Affairs - High Density Lipoprotein Cholesterol Intervention Trial (VA-HIT): Scientific Sessions of the American Heart Association. Dallas, USA: 11 November 1998. Plenary session XII 'Late breaking clinical trials'.
11. 11 Reddy JK, Qureshi SA. Tumorigenicity of the hypolipidaemic peroxisome proliferator ethyl-alpha-p-chlorophenoxyisobutyrate (clofibrate) in rats. Br J Cancer 1979; 40:476-482.
12. 12 Issemann I, Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 1990; 347:645-650.
13. 13 Gonzalez FJ, Peters JM, Cattley RC. Mechanism of action of the nongenotoxic peroxisome proliferators: role of the peroxisome proliferator-activator receptor alpha. J Natl Cancer Inst. 1998; 90:1702-1709.
14. 14 Vanden Heuvel JP. Peroxisome proliferator-activated receptors: a critical link among fatty acids, gene expression and carcinogenesis. J Nutr 1999; 129:575-580.
15. 15 Schoonjans K, Staels B, Auwerx J. The peroxisome proliferator activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation. Biochim Biophys Acta 1996; 1302:93-109.
16. 16 Heller F, Harvengt C. Effects of clofibrate, bezafibrate, fenofibrate and probucol on plasma lipolytic enzymes in normolipaemic subjects. Eur J Clin Pharmacol 1983; 25:57-63.
17. 17 Staels B, Vu-Dac N, Kosykh VA, Saladin R, Fruchart JC, Dallongeville J, et al. Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates. J Clin Invest 1995; 95:705-712.
18. 18 Malmendier CL, Delcroix C. Effects of fenofibrate on high and low density lipoprotein metabolism in heterozygous familial hypercholesterolemia. Atherosclerosis 1985; 55:161-169.
19. 19 Vu-Dac N, Schoonjans K, Laine B, Fruchart JC, Auwerx J, Staeils B. Negative regulation of the human apolipoprotein A-I promoter by fibrates can be attenuated by the interaction of the peroxisome proliferator-activated receptor with its response element. J Biol Chem 1994; 269:31012-31018.
20. 20 Vu-Dac N, Schoonjans K, Kosykh V, Dallongeville J, Fruchart JD, Staels B, et al. Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor. J Clin Invest 1995; 96:741-750.
21. 21 Cattin L, Da Col PG, Feruglio FS, Finazzo L, Rimondi S, Descovich G, et al. Efficacy of ciprofibrafe in primary type II and IV hyperlipidemia: the Italian multicenter study. Clin Ther 1990; 12:482-488.
22. 22 Tilly-Kiesi M, Tikkanen MJ. Low density lipoprotein density and composition in hypercholesterolaemic men treated with HMG CoA reductase inhibitors and gemfibrozil. J Intern Med 1991; 229:427-434.
23. 23 Caslake Mj, Packard Cj, Gaw A, Murray E, Friffin BA, Vallance BD, et al. Fenofibrate and LDL metabolic heterogeneity in hypercholesterolemia. Arterioscler Thromb 1993; 13:702-711.
24. 24 Stange EF, Fruhholz M, Osenbrugge M, Reimann F, Ditschuneit H. Bezafibrate fails to directly modulate HMG-CoA reductase or LDL catabolism in human mononuclear cells. Eur J Clin Pharmacol 1991; 40(Suppl 1):S37-S40.
25. 25 Martin G, Schoonjans K, Lefebvre AM, Staels B, Auwerx J. Coordinate regulation of the expression of the fatty acid transport protein and acyl-CoA synthetase genes by PPARalpha and PPARgamma activators. J Biol Chem 1997; 272:28210-28217.
26. 26 Motojima K, Passilly P, Peters JM, Gonzalez FJ, Latruffe N. Expression of putative fatty acid transporter genes are regulated by peroxisome proliferator-activated receptor alpha and gamma activators in a tissue-and inducer-specific manner. J Biol Chem 1998; 273:16710-16714.
27. 27 Mascaro C, Acosta E. Ortiz JA, Marrero PF, Hegardt FG, Haro D, et al. Control of human muscle-type carnitine palmitoyltransferase I gene transcription by peroxisome proliferator-activated receptor. J Biol Chem 1998; 273:8560-8563.
28. 28 Brandt JM, Djouadi F, Keily DP. Fatty acids activate transcription of the muscle carnitine palmitoyltransferase I gene in cardiac myocytes via the peroxisome proliferator-activated receptor alpha. J Biol Chem 1998; 273:23786-23792.
29. 29 Djouadi F, Weinheimer CJ, Saffitz JE, Pitchford C, Bastin J, Bonzalez FJ, et al. A gender-related defect in lipid metabolism and glucose homeostasis in peroxisome proliferator-activated receptor alpha-deficient mice. J Clin Invest 1998; 102:1083-1091.
30. 30 Meertens LM, Miyata KS, Cechetto JD, Rachubinski RA, Capone JP. A mitochondrial ketogenic enzyme regulates its gene expression by association with the nuclear hormone receptor PPARalpha. EMBO J 1998; 17:6972-6978.
31. 31 Kelly LJ, Vicario PP, Thompson GM, Candelore MR, Doebber TW, Ventre J, et al. Peroxisome proliferator-activated receptors gamma and alpha mediate in vivo regulation of uncoupling protein (UCP-1, UCP-2, UCP-3) gene expression. Endocrinology 1998; 139:4920-4927.
32. 32 Kesaniemi YA, Grundy SM. Influence of gemfibrozil and clofibrate on metabolism of cholesterol and plasma triglycerides in man. JAMA 1984; 251:2241-2246.
33. 33 Hahn SE, Goldberg DM. Modulation of lipoprotein production in Hep G2 cells by fenofibrate and clofibrate. Biochem Pharmacol 1992; 43:625-633.
34. 34 Desager JP, Horsmans Y, Vandenplas C, Harvengt C. Pharmacodynamic activity of lipoprotein lipase and hepatic lipase, and pharmacokinetic parameters measured in normolipidaemic subjects receiving ciprofibrate (100 or 200 mg/day) or micronised fenofibrate (200 mg/day) therapy for 23 days. Atherosclerosis 1996; 124(Suppl):S65-S73.
35. 35 Foger B, Drexel H, Hopferwieser T, Miesenbock G, Ritsch A, Lechleitner M, et al. Fenofibrate improves postprandial chylomicron clearance in II B hyperlipoproteinemia. Clin Invest 1994; 72:294-301.
36. 36 Schoonjans K, Peinado-Onsurbe J, Lefebvre AM, Heyman RA, Briggs M, Deeb S, et al. PPARalpha and PPARgamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J 1996; 15:5336-5348.
37. 37 Quarfordt SH, Michalopoulos G, Schirmer B. The effect of human C apolipoproteins on the in vitro hepatic metabolism of triglyceride emulsions in the rat. J Biol Chem 1982; 257:14642-14647.
38. 38 Windler E, Chao Y, Havel RJ. Regulation of the hepatic uptake of triglyceride-rich lipoproteins in the rat. Opposing effects of homologous apolipoprotein E and individual C apoproteins. J Biol Chem 1980; 255:8303-8307.
39. 39 Clavey V, Lestavel-Delattre S, Copin C, Bard JM, Fruchart JC. Modulation of lipoprotein B binding to the LDL receptor by exogenous lipids and apolipoproteins CI, CII, CIII, and E. Arterioscler Thromb Vasc Biol 1995; 15:963-971.
40. 40 Aalto-Setala K, Fisher EA, Chen X, Chajeck-Shaul T, Hayek T, Zechner R, et al. Mechanism of hypertriglyceridemia in human apolipoprotein (apo) CIII transgenic mice. Diminished very low density lipoprotein fractional catabolic rate associated with increased apo CIII and reduced apo E on the particles. J Clin Invest 1992; 90:1889-1900.
41. 41 Aalto-Setala K, Weinstock PH, Bisgaier CL, Wu L, Smith JD, Breslow JL, et al. Further characterization of the metabolic properties of triglyceride-rich lipoproteins from human and mouse apoC-III transgenic mice. J Lipid Res 1996; 37:1802-1811.
42. 42 Ebara T, Ramakrishnan R, Steiner G, Shachter NS. Chylomicronemia due to apotipoprotein CIII overexpression in apolipoprotein E-null mice. Apolipoprotein CIII-induced hypertriglyceridemia is not mediated by effects on apolipoprotein E. J Clin invest 1997; 99:2672-2681.
43. 43 Maeda N, Li H, Lee D, Oliver P, Quarfordt SH, Osada J, et al. Targeted disruption of the apolipoprotein C-III gene in mice results in hypotriglyceridemia and protection from postprandial hypertriglyceridemia. J Biol Chem 1994; 269:23610-23616.
44. 44 Li WW, Dammerman MM, Smith JD, Metzger S, Breslow JL, Leff T, et al. Common genetic variation in the promoter of the human apo CIII gene abolishes regulation by insulin and may contribute to hypertriglyceridemia. J Clin Invest 1995: 96:2601-2605.
45. 45 Malmendier CL, Lontie JF, Delcroix C, Dubois DY, Magot T, De Roy L, et al. Apolipoproteins C-II and C-III metabolism in hypertriglyceridemic patients. Effect of a drastic triglyceride reduction by combined diet restriction and fenofibrate administration. Atherosclerosis 1989; 77:139-149.
46. 46 Ginsberg HN, Le NA, Goldberg U, Gibson JC, Rubinstein A, Wang-Iverson P, et al. Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo. J Clin Invest 1986; 78:1287-1295.
47. 47 Bard JM, Parra HJ, Camare R, Luc G, Ziegler O, Dachet C, et al. A multicenter comparison of the effects of simvastatin and fenofibrate therapy in severe primary hypercholesterolemia, with particular emphasis on lipoproteins defined by their apolipoprotein composition. Metabolism 1992; 41:498-503.
48. 48 Haubenwallner S, Essenburg Ad, Barnett BC, Pape ME, Demattos RB, Krause BR, et al. Hypolipidemic activity of select fibrates correlates to changes in hepatic apolipoprotein C-III expression: a potential physiologic basis for their mode of action. J Lipid Res 1995; 36:2541-2551.
49. 49 Peters JM, Hennuyer N, Staels B, Fruchart JC, Fievet C, Gonzalez FJ, et al. Alterations in lipoprotein metabolism in peroxisorne proliferator-activated receptor alpha-deficient mice. J Biol Chem 1997; 272:27307-27312.
50. 50 Ladias Ja, Hadzopoulou-Cladaras M, Kardassis D, Cardot P, Chieng J, Zannis V, et al. Transcriptional regulation of human apolipoprotein genes ApoB, ApoCIII, and ApoAII by members of the steroid hormone receptor superfamily HNF-4, ARP-1, EAR-2, and EAR-3, J Biol Chem 1992; 267:15849-15860.
51. 51 Vu-Dac N, Gervois P, Pineda Torra IP, Fruchart JC, Kosykh V, Kooistra T, et al. Retinoids increase human apo C-III expression at the transcriptional level via the retinoid X receptor. Contribution to the hypertriglyceridemic action of retinoids. J Clin Invest 1998; 102:625-632.
52. 52 Hertz R, Bishara-Shieban J, Bar-Tana. Mode of action of peroxisome proliferators as hypolipidemic drugs. Suppression of apolipoprotein C-III. J Biol Chem 1995; 270:13470-13475.
53. 53 Vu-Dac N, Chopin-Delannoy S, Gervois P, Bonnelye E, Martin G, Fruchart JC, et al. The nuclear receptors peroxisome proliferator-activated receptor alpha and Rev-erb-alpha mediate the species-specific regulation of apolipoprotein A-I expression by fibrates. J Biol Chem 1998; 273:25713-25720.
54. 54 Gervois P, Chopin-Delannoy S, Fadel A, Dubois G, Kosykh V, Fruchart JC, et al. Fibrates increase human Rev-erb-alpha expression in liver via a novel PPAR response element. Mol Endocrinol 1999; 13:400-409.
55. 55 Duez H, Mansen A, Fruchart JC, Vennstrom B, Fievet C, Staels B. Rev-erb-alpha: a nuclear receptor with a role in lipoprotein metabolism. Circulation 1998; 98:17,1-449:2363.
56. 56 Sakai M, Matsushima-Hibiya Y, Nishizawa M, Nishi S. Suppression of rat glutathione transferase P expression by peroxisome proliferators: interaction between Jun and peroxisome proliferator-activated receptor alpha. Cancer Res 1995; 55:5370-5376.
57. 57 Poynter ME, Daynes RA. Peroxisome proliferator-activated receptor alpha activation modulates cellular redox status, represses nuclear factor-kappaB signaling, and reduces inflammatory cytokine production in aging. J Biol Chem 1998; 273:32833-32841.
58. 58 Staels B, Koenig W, Habib A, Merval R, Lebret M, Torra IP, et al. Activation of human aortic smooth-muscle cells is inhibited by PPAR but not by PPAR activators. Nature 1998; 393:790-793.
59. 59 Zhou YC, Waxman DJ. Cross-talk between janus kinase-signal transducer and activator of transcription (JAK-STAT) and peroxisome proliferator-activated receptor-alpha (PPAR) signaling pathways. Growth hormone inhibition of Paralpha transcriptional activity mediated by STAT5b. J Biol Chem 1999; 274:2672-2681.
60. 60 Kahri J, Sane T, Van Tol A, Taskinen MR. Effect of gemfibrozil on the regulation of HDL subfractions in hypertriglyceridaemic patients. J Intern Med 1995; 238:429-436.
61. 61 Zambon D, Ros E, Rodriguez-Villar C, Laguna JC, Vazquez M, Sanllehy C, et al. Randomized crossover study of gemfibrozil versus lovastatin in familial combined hyperlipidemia: additive effects of combination treatment on lipid regulation. Metabolism 1999; 48:47-54.
62. 62 Steinmetz A, Schwartz T, Hehnke U, Kaffarnik H. Multicenter comparison of micronized fenofibrate and simvastatin in patients with primary type IIA or IIB hyperlipoproteinemia. J Cardiovasc Pharmacol 1996; 27:563-570.
63. 63 Schaefer EJ, Lamon-Fava S, Cole T, Sprecher DI, Cilla DDJ, Balagtas CC, et al. Effects of regular and extended-release gemfibrozil on plasma lipoproteins and apolipoproteins in hypercholosterolemic patients with decreased HDL cholesterol levels. Atherosclerosis 1996; 127:113-122.
64. 64 Staels B, Van Tol A, Andreu T, Auwerx J. Fibrates influence the expression of genes involved in lipoprotein metabolism in a tissue-selective manner in the rat. Arterioscler Thromb 1992; 12:286-294.
65. 65 Berthou L, Saladin R, Yaqoob P, Branellec D, Calder P, Fruchart JC, et al. Regulation of rat liver apolipoprotein A-I, apolipoprotein A-II and acylcoenzyme A oxidase gene expression by fibrates and dietary fatty acids. Eur J Biochem 1995; 232:179-187.
66. 66 Berthou L, Duverger N, Emmanuel F, Langouet S, Auwerx J, Guillouzo A, et al. Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apolipoprotein A-I transgenic mice. J Clin Invest 1996; 97:2408-2416.
67. 67 Kockx M, Princen Hm, Kooistra T. Fibrate-modulated expression of fibrinogen, plasminogen activator inhibitor-1 and apolipoprotein A-I in cultured cynomolgus monkey hepatocytes: role of the peroxisome proliferator-activated receptor alpha. Thromb Haemost. 1998; 80:942-948.
68. 68 Costet P, Legendre C, More J, Edgar A, Galtier P, Pineau T, et al. Peroxisome proliferator-activated receptor alpha-isoform deficiency leads to progressive dyslipidemia with sexually dimorphic obesity and steatosis. J Biol Chem 1998; 273:29577-29585.
69. 69 Reddy JK, Scarpelli Dg, Subbarao V, Lalwani ND. Chemical carcinogens without mutagenic activity: peroxisome proliferators as a prototype. Toxicol Pathol 1983; 11:172-180.
70. 70 Hennuyer N, Poulain P, Madsen L, Berge RI, Houdebine LM, Branellec D, et al. The beneficial effects of fibrates on high density lipoprotein metabolism occur independent of any peroxisome proliferative response. Circulation 1999 (in press).
71. 71 Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362:801-809.
72. 72 Tontonoz P, Nagy L, Alvarez JG, Thomazy VA, Evans RM. PPAR-gamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 1998; 93:241-252.
73. 73 Ricote M, Huang J, Fajas L, Li A, Welch J, Najib J, et al. Expression of the peroxisome proliferator-activated receptor gamma (PPAR) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. Proc Natl Acad Sci U S A 1998; 95:7614-7619.
74. 74 Marx N, Sukhova G, Murphy C, Libby P, Plutzky J. Macrophages in human atheroma contain PPAR-gamma: differentiation-dependent peroxisomal proliferator-activated receptor gamma expression and reduction of MMP-9 activity through PPAR-gamma activation in mononuclear phagocytes in vitro. Am J Pathol 1998; 153:17-23.
75. 75 Hahmann HW, Bunte T, Hellwig N, Hau U, Becker D, Dyckmans J, et al. Progression and regression of minor coronary arterial narrowings by quantitative angiography after fenofibrate therapy. Am J Cardiol 1991; 67:957-961.
76. 76 Bunte T, Hahmann HW, Hellwig N, Hau U, Becker D, Dyckmans J, et al. Effects of fenofibrate on angiographically examined coronary atherosclerosis and left ventricular function in hypercholesterolemic patients. Atherosclerosis 1993; 98:127-138.
77. 77 Ericsson CG, Hamsten A, Nilsson J, Grip L, Svane B, De Faire U, et al. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet 1996; 347:849-853.
78. 78 Frick MH, Syvanne M, Nieminen MS, Kauma H, Majahalme S, Virtanen V, et al. Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study Group. Circulation 1997; 96:2137-2143.
79. 79 Law RE, Meehan WP, Xi XP, Graf K, Wuthrich DA, Coats W, et al. Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia. J Clin Invest 1996; 98:1897-1905.
80. 80 Murakam T, Mizuno S, Ohnaka M. Troglitazone restores endothelium-dependent vasomotion of resistance coronary artery. Circulation 1998; 98:17,1-111:564.
81. 81 Watanabe Y, Sunayama S, Mokumo H. Troglitazone improves endothelial function in patients with insulin resistance. Circulation 1998; 98:17,1-111:566.
82. 82 Kawasaki J, Hirano K, Nishimura J, Fujishima M, Kanaide H. Mechanisms of vasorelaxation induced by troglitazone, a novel antidiabetic drug, in the porcine coronary artery. Circulation 1998; 98:2446-2452.
83. 83 Minamikawa J, Tanaka S, Yamauchi M, Inoue D, Koshiyama H. Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 1998; 83:1818-1820.
84. 84 Inoue I, Shino K, Noji S, Awata T, Katayama S. Expression of peroxisome proliferator-activated receptor alpha (PPAR-alpha) in primary cultures of human vascular endothelial cells. Biochem Biophys Res Commun 1998; 246:370-374.
85. 85 Delerive P, Martin-Nizard F, Chinetti G, Trottein F, Fruchart JC, Duriez P, et al. PPAR activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells. Circulation 1998; 98:17,1-406:2137.
86. 86 Iijima K, Yoshizumi M, Ako J, Eto M, Kim S, Hashimoto M, et al. Expression of peroxisome proliferator-activated receptor gamma (PPAR-alpha) in rat aortic smooth muscle cells. Biochem Biophys Res Commun 1998; 247:353-356.
87. 87 Chinetti G, Griglio S, Antonucci M et al. Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages. J Biol Chem 1998; 273:25573-25580.
88. 88 Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 1998; 391:79-82.
89. 89 Nagy L, Tontonoz P, Alvarez JG, Chen H, Evans RM. Oxidized LDL regulates macrophage gene expression through ligand activation of PPAR-alpha. Cell 1998; 93:229-240.
90. 90 Devchand PR, Keller H, Peters JM, Vazquez M, Gonzalez FJ, Wahli W. The PPAR-alpha-leukotriene B4 pathway to inflammation control. Nature 1996; 384:39-43.
91. 91 Jiang C, Ting AT, Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 1998; 391:82-86.
92. 92 Marx N, Schonbeck U, Lazar MA, Libby P, Plutzky J. Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells. Circ Res 1998; 83:1097-1103.
93. 93 Colville-Nash PR, Qureshi SS, Willis D, Willoughby D. Inhibition of inducible nitric oxide synthase by peroxisome proliferator-activated receptor agonists: correlation with induction of heme oxygenase 1. J Immunol 1998; 161:978-984.
94. 94 Satoh H, Tsukamoto K, Hashimoto Y, Hashimoto N, Togo M, Hara M, et al. Thiazolidinediones suppress endothelin-1 secretion from bovine vascular endothelial cells: a new possible role of PPAR-gamma on vascular endothelial function. Biochem Biophys Res Commun 1999; 254:757-763.
95. 95 Marx N, Bourcier T, Sukhova G, Plutzky J. Human endothelial cells contain PPARs: evidence for PPAR-alpha in atheroma and its regulation of PAI-1 expression. Circulation 1998; 98:17,1-383:2010.
96. 96 Arts J, Kockx M, Princen HM, Kooistra T. Studies on the mechanism of fibrate-inhibited expression of plasminogen activator inhibitor-1 in cultured hepatocytes from cynomolgus monkey. Arterioscler Thromb Vasc Biol 1997; 17:26-32.
97. 97 Durrington PN, Mackness MI, Bhatnagar D, Julier K, Prais H, Arrol S, et al. Effects of two different fibric acid derivatives on lipoproteins, cholesteryl ester transfer, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in type IIb hyperlipoproteinaemia. Atherosclerosis 1998; 138:217-225.
98. 98 Kockx M, De Maat MP, Knipscheer HC, Kastelein JJ, Kluft C, Princen HM, et al. Effects of gemfibrozil and ciprofibrate on plasma levels of tissue-type plasminogen activator, plasminogen activator inhibitor-1 and fibrinogen in hyperlipidaemic patients. Thromb Haemost 1997; 78:1167-1172.
99. 99 Kockx M, Gervois P, Poulain P, Derudas B, Peters JM, Gonzalez FJ, et al. Fibrates suppress fibrinogen gene expression in rodents via activation of the peroxisome proliferator-activated receptor-alpha. Blood 1999; 93:2991-2998.